MRVI - Maravai LifeSciences Holdings Non-GAAP EPS of $0.03 misses by $0.01 revenue of $79M misses by $0.72M

2023-05-08 16:17:27 ET

• Maravai LifeSciences Holdings press release ( NASDAQ: MRVI ): Q1 Non-GAAP EPS of $0.03 misses by $0.01 .
• Revenue of $79M (-67.7% Y/Y) misses by $0.72M .

• Updated Financial Guidance for 2023

  Our financial guidance for the full year 2023 is based on expectations for our existing business and does not include the financial impact of potential new acquisitions, if any, or items that have not yet been identified or quantified. This guidance is subject to a number of risks, uncertainties and other factors, including those identified in “Forward-looking Statements” below.

  Total revenue for 2023 is projected to be in the range of $400.0 million to $440.0 million, vs. consensus of $430.19M

  Adjusted EBITDA (non-GAAP) is expected to be in the range of $155.0 million to $175.0 million.

  Adjusted fully diluted EPS (non-GAAP) is expected to be in the range of $0.27 to $0.33 per share,vs. consensus of $0.36

For further details see: